No Evident Systemic Terminal Complement Pathway Activation in Hidradenitis Suppurativa

J Invest Dermatol. 2021 Dec;141(12):2966-2969.e1. doi: 10.1016/j.jid.2021.03.037. Epub 2021 Jul 9.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Case-Control Studies
  • Clinical Trials as Topic
  • Complement Activation*
  • Complement C5a / immunology
  • Complement System Proteins*
  • Female
  • Hidradenitis Suppurativa / blood
  • Hidradenitis Suppurativa / immunology*
  • Humans
  • Immunotherapy / methods*
  • Male
  • Middle Aged

Substances

  • Complement C5a
  • Complement System Proteins

Associated data

  • ClinicalTrials.gov/NCT03001622
  • ClinicalTrials.gov/NCT03487276